Prohemostatic Interventions in Trauma: Resuscitation-Associated Coagulopathy, Acute Traumatic Coagulopathy, Hemostatic Resuscitation, and Other Hemostatic Interventions

Benjamin M. Howard; Aaron T. Daley; Mitchell Jay Cohen

doi:10.1055/s-0032-1306435

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2012; 38(03): 250-258
DOI: 10.1055/s-0032-1306435

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Prohemostatic Interventions in Trauma: Resuscitation-Associated Coagulopathy, Acute Traumatic Coagulopathy, Hemostatic Resuscitation, and Other Hemostatic Interventions

Authors

Benjamin M. Howard

¹Department of Surgery, University of California, San Francisco, California
Aaron T. Daley

²Department of Surgery, San Francisco General Hospital, San Francisco, California
Mitchell Jay Cohen

²Department of Surgery, San Francisco General Hospital, San Francisco, California

Abstract

Trauma is the most common cause of death in the young and hemorrhage is the most important cause of death in patients with trauma. Recently redefined pathways of inflammation and coagulation, together with hypothermia and acidosis contribute to trauma-associated coagulopathy and aggravation of bleeding. Pharmacological prohemostatic agents may be useful to (partly) correct the coagulopathy in trauma patients and may serve as useful adjunctive treatment options in patients with severe blood loss after trauma. Recombinant factor VIIa, fibrinogen and prothrombin complex concentrates, and antifibrinolytic agents have been evaluated in clinical trials. These interventions show promising effects but their efficacy in reducing clinically important outcome parameters need to be confirmed in clinical studies.

Keywords

trauma - coagulopathy - acute traumatic coagulopathy - hemostatic resuscitation - hemostatic interventions

Volltext

Referenzen

References
1 World Health Organization. Injury Chart Book. Geneva. Available at: http://whqlibdoc.who.int/publications/924156220x.pdf . Accessed on January 15, 2012
2 An G. In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling. Crit Care Med 2004; 32 (10) 2050-2060
3 Holcomb JB, McMullin NR, Pearse L , et al. Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004. Ann Surg 2007; 245 (6) 986-991
4 Hess JR, Holcomb JB, Hoyt DB. Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion 2006; 46 (5) 685-686
5 Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007; 13 (6) 680-685
6 Cohen MJ, Call M, Nelson M , et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 2012; 255 (2) 379-385
7 Cohen MJ, Brohi K, Ganter MT, Manley GT, Mackersie RC, Pittet JF. Early coagulopathy after traumatic brain injury: the role of hypoperfusion and the protein C pathway. J Trauma 2007; 63 (6) 1254-1261 ; discussion 1261–1252
8 Hess JR, Brohi K, Dutton RP , et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65 (4) 748-754
9 Bouillon B, Brohi K, Hess JR, Holcomb JB, Parr MJ, Hoyt DB. Educational initiative on critical bleeding in trauma: Chicago, July 11-13, 2008. J Trauma 2010; 68 (1) 225-230
10 Duchesne JC, McSwain Jr NE, Cotton BA , et al. Damage control resuscitation: the new face of damage control. J Trauma 2010; 69 (4) 976-990
11 Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54 (6) 1127-1130
12 Holcomb JB, Wade CE, Michalek JE , et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248 (3) 447-458
13 Borgman MA, Spinella PC, Perkins JG , et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63 (4) 805-813
14 Smith CE, Yamat RA. Avoiding hypothermia in the trauma patient. Curr Opin Anaesthesiol 2000; 13 (2) 167-174
15 Tsuei BJ, Kearney PA. Hypothermia in the trauma patient. Injury 2004; 35 (1) 7-15
16 Waibel BH, Schlitzkus LL, Newell MA, Durham CA, Sagraves SG, Rotondo MF. Impact of hypothermia (below 36 degrees C) in the rural trauma patient. J Am Coll Surg 2009; 209 (5) 580-588
17 Wolberg AS, Meng ZH, Monroe III DM, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56 (6) 1221-1228
18 Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94 (1) 199-207
19 Martini WZ. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009; 67 (1) 202-208, discussion 208–209
20 Dirkmann D, Hanke AA, Görlinger K, Peters J. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106 (6) 1627-1632
21 Engström M, Schött U, Romner B, Reinstrup P. Acidosis impairs the coagulation: A thromboelastographic study. J Trauma 2006; 61 (3) 624-628
22 Hirshberg A, Dugas M, Banez EI, Scott BG, Wall Jr MJ, Mattox KL. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54 (3) 454-463
23 Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care 2005; 11 (6) 590-597
24 Maegele M, Lefering R, Yucel N , et al; AG Polytrauma of the German Trauma Society (DGU). Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38 (3) 298-304
25 Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010; 105 (2) 116-121
26 Martini WZ. Fibrinogen availability and coagulation function after hemorrhage and resuscitation in pigs. Mol Med 2011; 17 (7–8) 757-761
27 Martini WZ, Holcomb JB. Acidosis and coagulopathy: the differential effects on fibrinogen synthesis and breakdown in pigs. Ann Surg 2007; 246 (5) 831-835
28 MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55 (1) 39-44
29 Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?. Ann Surg 2007; 245 (5) 812-818
30 Frith D, Brohi K. The acute coagulopathy of trauma shock: clinical relevance. Surgeon 2010; 8 (3) 159-163
31 Frith D, Goslings JC, Gaarder C , et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost 2010; 8 (9) 1919-1925
32 Chesebro BB, Rahn P, Carles M , et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 2009; 32 (6) 659-665
33 Esmon CT. The protein C pathway. Chest 2003; 124 (3, Suppl) 26S-32S
34 Mosnier LO, Zampolli A, Kerschen EJ , et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113 (23) 5970-5978
35 Holcomb JB, Jenkins D, Rhee P , et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007; 62 (2) 307-310
36 Silverboard H, Aisiku I, Martin GS, Adams M, Rozycki G, Moss M. The role of acute blood transfusion in the development of acute respiratory distress syndrome in patients with severe trauma. J Trauma 2005; 59 (3) 717-723
37 Cotton BA, Gunter OL, Isbell J , et al. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008; 64 (5) 1177-1182; discussion 1182–1183 ,
38 Alam HB, Rhee P. New developments in fluid resuscitation. Surg Clin North Am 2007; 87 (1) 55-72 , vi,
39 Rowell SE, Barbosa RR, Diggs BS , et al; Trauma Outcomes Group. Effect of high product ratio massive transfusion on mortality in blunt and penetrating trauma patients. J Trauma 2011; 71 (2, Suppl 3) S353-S357
40 Brown LM, Aro SO, Cohen MJ , et al; Trauma Outcomes Group. A high fresh frozen plasma: packed red blood cell transfusion ratio decreases mortality in all massively transfused trauma patients regardless of admission international normalized ratio. J Trauma 2011; 71 (2, Suppl 3) S358-S363
41 Pati S, Matijevic N, Doursout MF , et al. Protective effects of fresh frozen plasma on vascular endothelial permeability, coagulation, and resuscitation after hemorrhagic shock are time dependent and diminish between days 0 and 5 after thaw. J Trauma 2010; 69 (Suppl. 01) S55-S63
42 Magnotti LJ, Zarzaur BL, Fischer PE , et al. Improved survival after hemostatic resuscitation: does the emperor have no clothes?. J Trauma 2011; 70 (1) 97-102
43 Snyder CW, Weinberg JA, McGwin Jr G , et al. The relationship of blood product ratio to mortality: survival benefit or survival bias?. J Trauma 2009; 66 (2) 358-362; discussion 362–354 ,
44 Duchesne JC, Barbeau JM, Islam TM, Wahl G, Greiffenstein P, McSwain Jr NE. Damage control resuscitation: from emergency department to the operating room. Am Surg 2011; 77 (2) 201-206
45 Rahbar MH, Fox EE, Del Junco DJ , et al; The PROMMTT Investigators. Coordination and management of multicenter clinical studies in trauma: Experience from the PRospective Observational Multicenter Major Trauma Transfusion (PROMMTT) Study. Resuscitation 2011; .
46 Park MS, Martini WZ, Dubick MA , et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67 (2) 266-275; discussion 275–266 ,
47 Kashuk JL, Moore EE, Wohlauer M , et al. Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy. Transfusion 2012; 52 (1) 23-33
48 Kashuk JL, Moore EE, Sawyer M , et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. Ann Surg 2010; 251 (4) 604-614
49 Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 45
50 Deveras RA, Kessler CM. Reversal of waxfarin-induced anticoagulation with recombinant human factor VIIA concentrate. Ant Int Med 2002; 137 (11) 884-888
51 Friederich PW, Henny CP, Messelink EJ , et al. Effect of recombinant activated Factor VII on perioperative blood in patients undergoing retropubic prostatectomy: a double-blinded, placebo-controlled randomized trial. Lancet 2003; 361: 201-205
52 Morey AF. Factor VIIa for correction of traumatic coagulopathy. J Urol 2005; 174 (3) 968
53 Dutton RP, McCunn M, Hyder M , et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57 (4) 709-718 ; discussion 718–709
54 Spinella PC, Perkins JG, McLaughlin DF , et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008; 64 (2) 286-293; discussion 293–284 ,
55 Dutton R, Hauser C, Boffard K , et al; CONTROL Steering Committee. Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding. Clin Trials 2009; 6 (5) 467-479
56 Boffard KD, Riou B, Warren B , et al; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59 (1) 8-15 , discussion 15–18
57 Hauser CJ, Boffard K, Dutton R , et al; CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69 (3) 489-500
58 O'Connell KA, Wood JJ, Wise RP , et al. Thromboembolic adverse events after use of recombinant human coagulation Factor VIIa. JAMA 2006; 295 (3) 293-298
59 Zaaroor M, Soustiel JF, Brenner B, Bar-Lavie Y, Martinowitz U, Levi L. Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy. Acta Neurochir (Wien) 2008; 150 (7) 663-668
60 McMullin NR, Kauvar DS, Currier HM, Baskin TW, Pusateri AE, Holcomb JB. The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy. Curr Surg 2006; 63 (4) 246-251
61 Knudson MM, Cohen MJ, Reidy R , et al. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg 2011; 212 (1) 87-95
62 Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81 (2) 360-365
63 Thorarinsdottir HR, Sigurbjornsson FT, Hreinsson K, Onundarson PT, Gudbjartsson T, Sigurdsson GH. Effects of fibrinogen concentrate administration during severe hemorrhage. Acta Anaesthesiol Scand 2010; 54 (9) 1077-1082
64 Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15 (5) R239
65 Stinger HK, Spinella PC, Perkins JG , et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64 (Suppl. 02) S79-85; discussion S85 ,
66 Meyer MA, Ostrowski SR, Windeløv NA, Johansson PI. Fibrinogen concentrates for bleeding trauma patients: what is the evidence?. Vox Sang 2011; 101 (3) 185-190
67 Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011; 45 (7–8) 990-999
68 Innerhofer P. Fibrinogen and prothrombin complex concentrate for the management of massive bleeding. Wien Klin Wochenschr 2010; 122 (Suppl. 05) S16-S17
69 Dickneite G, Dörr B, Kaspereit F, Tanaka KA. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma 2010; 68 (5) 1151-1157
70 Pragst I, Kaspereit F, Dörr B, Dickneite G. Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model. Thromb Res 2010; 125 (3) 272-277
71 Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth 2009; 102 (3) 345-354
72 Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119 (5) 643-651
73 Schöchl H, Nienaber U, Maegele M , et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15 (2) R83
74 CRASH-2 collaborators, Roberts I, Shakur H. , et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-1101, 1101 e1091–1092 ,
75 Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) study. Arch Surg 2011;
76 Roberts I, Shakur H, Ker K, Coats T ; CRASH-2 Trial collaborators. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011; CD004896 (1) CD004896
77 Granville-Chapman J, Jacobs N, Midwinter MJ. Pre-hospital haemostatic dressings: a systematic review. Injury 2011; 42 (5) 447-459
78 Perkins JG, Cap AP, Weiss BM, Reid TJ, Bolan CD. Massive transfusion and nonsurgical hemostatic agents. Crit Care Med 2008; 36 (7, Suppl) S325-S339
79 Bowman PD, Wang X, Meledeo MA, Dubick MA, Kheirabadi BS. Toxicity of aluminum silicates used in hemostatic dressings toward human umbilical veins endothelial cells, HeLa cells, and RAW267.4 mouse macrophages. J Trauma 2011; 71 (3) 727-732
80 Watters JM, Van PY, Hamilton GJ, Sambasivan C, Differding JA, Schreiber MA. Advanced hemostatic dressings are not superior to gauze for care under fire scenarios. J Trauma 2011; 70 (6) 1413-1419